Leonhardt Ventures taps REV•1 Engineering to design and develop Valvublator’s heart valve regeneration technology platform. MURRIETA, Calif. – July 26, 2019 – REV•1 Engineering has been selected as the exclusive design and development partner for the commercialization of Valvublator’s advanced, combination drug/device/biologics technology for regenerating human heart valves. Valvublator’s platform integrates mechanical, electrical, therapeutical, and biological elements in a single, minimally invasive catheter to decalcify, cell sod and regenerate a patient’s heart valve leaflets. It is intended […]